Thomas Hope, MD, raised concerns about HR 2541, the Nuclear Medicine Clarification Act of 2025, which aims to enhance reporting on radiopharmaceutical leakage. He argues the legislation does not address significant clinical issues, noting that he has not seen any adverse effects from infiltration of radiopharmaceuticals in his extensive experience. Hope emphasizes that while infiltrations can occur with any intravenous medication, the clinical significance of reporting these events is questionable. He questions whether the bill will improve patient care, as it may complicate workflows and adds little value to clinical outcomes. Additionally, he points out that the Nuclear Regulatory Commission (NRC) is already working on relevant guidelines, suggesting the bill may be unnecessary. Hope advocates for allowing the NRC's ongoing process to continue rather than imposing this legislative change.
Sat, 29 Nov 2025 15:06:51 GMT | CancerNetwork